VYNE Therapeutics | Evaluate

October 05, 2020

Few clues to flotation fever in past performance

Investors are piling into biotech IPOs, but the track record of previous years' new issues shows how hard it is to pick winners.

Another venture funding surge sets up a strong 2018

Cell and gene therapy companies dominate the first quarter, but companies outside these fashionable areas are finding it harder to charm VCs.

April 09, 2018

First-quarter floats hold amid uncertain climate

Biotech IPOs record another strong quarter, setting the pace for a bumper year of new issues.